TB-500 (10 mg Vial)

TB-500 (10 mg Vial) Dosage Chart

TB-500 is dosed at 500 mcg–1 mg daily via subcutaneous injection in educational protocols. A 10 mg vial reconstituted with bacteriostatic water yields about 3.33 mg/mL. This information is for research and educational use only.

TB-500 is a synthetic peptide fragment corresponding to the active region of thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid protein involved in tissue repair and regeneration.

This educational protocol presents a once-daily subcutaneous approach using a practical dilution for accurate insulin syringe measurements in research settings.

Educational guide for reconstitution and weekly dosing

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

Phase	Daily Dose (mcg)	Units (per injection) (mL)
Weeks 1–2	500 mcg	15 units (0.15 mL)
Weeks 3–4	600 mcg	18 units (0.18 mL)
Weeks 5–8	750 mcg	23 units (0.23 mL)
Weeks 9–12	1000 mcg	30 units (0.30 mL)

Frequency: Inject once daily subcutaneously. This schedule uses the largest practical dilution (3.0 mL) to keep per-injection units in a comfortable range for accurate measurement. Total weekly dose averages ~5 mg, consistent with research protocols.

Reconstitution Steps

Plan based on an 8–16 week daily protocol with gradual titration.

Concise summary of the once-daily regimen.

Goal: Support tissue repair, wound healing, and angiogenesis through the active thymosin beta-4 fragment mechanism.
Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if research goals require).
Dose Range: 500–1000 mcg daily with gradual titration (~5 mg/week average).
Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for accurate unit measurements.
Storage: Lyophilized frozen; reconstituted refrigerated; avoid freeze–thaw cycles of the reconstituted solution.

Suggested daily titration approach.

Start: 500 mcg daily; increase by approximately 100–150 mcg every 2 weeks as tolerated.
Target: 750–1000 mcg daily by Weeks 5–12.
Frequency: Once per day (subcutaneous).
Cycle Length: 8–12 weeks; optional extension to 16 weeks based on the research protocol.
Timing: Any consistent time each day; rotate injection sites systematically.

Proper storage preserves peptide quality and activity.

Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); do not freeze the reconstituted solution, as freezing can denature peptides.
Allow vials to reach room temperature before opening to reduce condensation uptake.
Use reconstituted vials within 28 days when stored with bacteriostatic water preservative.

Practical considerations for consistency and safety in research protocols.

Use a new sterile insulin syringe for each injection; dispose of it in a sharps container.
Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation and lipohypertrophy.
Inject slowly; wait a few seconds before withdrawing the needle to help prevent backflow.
Document the daily dose, injection site, and any observations to maintain consistency.
Regulatory Note: TB-500 is banned by WADA for athletic use and is not FDA-approved for human administration.

TB-500 represents the N-terminal active fragment of thymosin beta-4, specifically the heptapeptide sequence Ac-LKKTETQ. This region is responsible for the actin-binding and cell-migration properties of the full thymosin molecule. Preclinical studies demonstrate that TB-500 promotes angiogenesis, accelerates wound healing, and supports tissue regeneration by upregulating cell motility and blood vessel formation. Research in animal models shows enhanced collagen deposition and reduced healing time in injury sites treated with thymosin fragments. Recent metabolic studies suggest TB-500 may act as a prodrug, cleaving to an active pentapeptide metabolite that drives biological activity.

Observations from preclinical and veterinary literature.

Supports accelerated wound healing and tissue repair through enhanced angiogenesis and cell migration.
May reduce inflammation and fibrosis indirectly via thymosin pathways observed in animal models.
Generally well tolerated in veterinary studies; occasional mild injection-site reactions (redness, tenderness) have been reported.
Human safety data is limited; no large-scale clinical trials have been completed specifically for TB-500.

Complementary strategies for optimal outcomes.

Pair with a balanced, protein‑forward diet tailored to individual energy needs.
Combine resistance training and aerobic activity to support metabolic health and preserve lean mass.
Prioritize adequate sleep (7–9 hours) and stress management for adherence and recovery.
Monitor hydration and electrolytes, especially if experiencing gastrointestinal side effects.

General subcutaneous guidance from clinical best‑practice resources

Clean the vial stopper and skin with alcohol; allow to air dry completely.
Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
Do not aspirate for subcutaneous injections; inject slowly and steadily.
Hold for 5–10 seconds before withdrawing the needle to ensure complete delivery.
Rotate sites systematically (abdomen, thighs, upper arms) each week to avoid lipohypertrophy.

We recommend Vitality Labs Blueprint Peptides for high‑purity TB‑500 (10 mg).

Why Vitality Labs Blueprint Peptides?

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. TB‑500 is not approved by the FDA for human use and is for research purposes only. TB‑500 is a prohibited substance in competitive sports under WADA regulations.

FASEB Journal

— Biological activities of thymosin β4 defined by active peptide sequences (TB‑500 fragment identification)

Journal of Chromatography A (PubMed)

— Doping control analysis of TB‑500 as synthetic thymosin β4 fragment in biological samples

WADA Scientific Research

— Investigation of TB‑500 metabolism, synthesis of metabolites, and detection limits

Racing Medication & Testing Consortium

— Thymosin β4 regulatory bulletin (TB‑500 use in equine sports medicine)

Journal of Investigative Dermatology (PubMed)

— Thymosin beta4 accelerates wound healing (preclinical wound healing model)

FASEB Journal (PubMed)

— Active site mapping of thymosin β4 fragments for angiogenesis and cell migration

Verified Peptides Storage Guide

— Lyophilized peptide storage best practices (temperature, humidity, light protection)

Empower Pharmacy

— Bacteriostatic water injection guidelines (0.9% benzyl alcohol, multi‑dose vial stability)

NCBI Bookshelf

— Best practices for subcutaneous injection (aseptic technique, site rotation)

WADA Prohibited List

— TB‑500 classification as prohibited substance in competitive sports

Journal of Investigative Dermatology

— Thymosin β4 wound healing mechanisms (collagen deposition, angiogenesis, granulation tissue)

Journal of Chromatography B (PubMed)

— Quantification of TB‑500 metabolites and wound healing activity screening (prodrug hypothesis)

CenterWatch Clinical Trials

— Clinical trial registry for thymosin β4 in acute myocardial infarction (no TB‑500 specific trials)

Nursing Journal (LWW)

— How to administer subcutaneous injections (clinical technique guidelines)

University of Michigan Health

— Patient education guide for subcutaneous injection technique

Vitality Lab Peptides

— TB‑500 (10 mg) product page (purity specifications and batch documentation)